2023年8月26日 · In this double-blind, randomized trial, we assigned ambulatory patients with heart failure, a left ventricular ejection fraction of 40% or less, and iron deficiency, in a 1:1 ratio, to receive...

Ferric carboxymaltose (FCM) is a novel non-dextran intravenous iron form which has been approved for use in patients with iron deficiency who have had inadequate response to oral iron therapy, intolerance to oral iron, or nondialysis-dependent chronic kidney disease.

2021年7月26日 · Iron is an essential nutrient that is necessary for oxygen delivery and metabolic homeostasis, and patients with HFrEF are at risk of developing absolute and functional ID. There are now 4 randomized clinical trials that have evaluated the effect of intravenous FCM in patients with ID and HFrEF.

Ferric carboxymaltose (FCM, Ferinject) was effective and well tolerated in the treatment of iron-deficiency anemia (IDA) in nine, Phase III, randomized, controlled, multicenter trials in a diverse range of indications, including patients with inflammatory bowel disease (IBD), post-partum anemia (PPA …

2023年8月17日 · In AFFIRM-AHF, treatment of iron deficiency with intravenous ferric carboxymaltose (FCM) reduced the risk of heart failure (HF) hospitalization and improved quality of life (QoL) vs placebo in patients stabilized following an acute HF (AHF) episode, with no effect on cardiovascular (CV) death.

2014年12月11日 · The present review on FCM summarizes diverse aspects such as pharmacology characteristics and analyzes trials on the efficacy/safety of FCM versus oral iron and different iv iron compounds in multiple clinical scenarios. Additionally, the information on cost effectiveness and data on change in quality of life are also discussed.

2023年5月19日 · Intravenous (IV) iron formulations circumvent malabsorption and rapidly restore hemoglobin. This Phase 2, non-randomized, multicenter study characterized the safety profile and determined...

2015年3月14日 · Treatment of symptomatic, iron-deficient HF patients with FCM over a 1-year period resulted in sustainable improvement in functional capacity, symptoms, and QoL and may be associated with risk reduction of hospitalization for worsening HF (ClinicalTrials.gov number NCT01453608).

Ferric Carboxymaltose is used in the treatment of iron deficiency anemia and anemia due to chronic kidney disease. Ferric Carboxymaltose is an anti-anemic medication. It replenishes the iron stores in your body. Iron is vital for the formation of new red blood cells and hemoglobin, a substance that gives these cells the ability to transport oxygen.

Ferric carboxymaltose (FCM) also known as FERINJECT® is an intravenous (IV) iron preparation, a medicine that is used in the treatment of iron deficiency conditions such as iron-deficiency anaemia (IDA). It contains iron in the form of ferric carboxymaltose, an …